Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome

Fibroblast growth factor-21 (FGF21) is elevated in patients with the metabolic syndrome. Although the exact underlying mechanisms remain ill-defined, chronic low-grade inflammation with increased Interleukin-(IL)-1β expression may be responsible. The aim of this study was to investigate effects of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahimi, Fahim, Urwyler, Sandrine Andrea, Betz, Matthias Johannes, Christ, Emanuel Remigius, Schuetz, Philipp, Mueller, Beat, Donath, Marc Yves, Christ-Crain, Mirjam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041761/
https://www.ncbi.nlm.nih.gov/pubmed/33846498
http://dx.doi.org/10.1038/s41598-021-87207-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041761/
https://www.ncbi.nlm.nih.gov/pubmed/33846498
http://dx.doi.org/10.1038/s41598-021-87207-w

Ejemplares similares